View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Wedbush Research
  • Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
GME GAMESTOP CORP. CLASS A
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
BLDR BUILDERS FIRSTSOURCE INC.
EA ELECTRONIC ARTS INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ISR ISORAY
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
PINS PINTEREST INC. CLASS A
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
U UNITY SOFTWARE
TVTX TRAVERE THERAPEUTICS INC
UFPI UFP INDUSTRIES INC.
VRDN VIRIDIAN THERAPEUTICS INC
IMNM IMMUNOME
PLTK PLAYTIKA HOLDING
NUVB NUVATION BIO INC (A)
RBLX ROBLOX
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
TCRX TSCAN THERAPEUTICS INC
APP APPLOVIN CORP
ATXS ASTRIA THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
VIGL VIGIL NEUROSCIENCE INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
NUVL NUVALENT INC
ARTV ARTIVA BIOTHERAPEUTICS INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
APGE APOGEE THERAPEUTICS INC
SKLZ SKILLZ INC
EMBRAC B EMBRACER GROUP AB
BCAX BICARA THERAPEUTICS INC.

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Take-Two Interactive Software, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 23 May 2025 in which we reassessed the appropriateness of the ratings i...

Alicia Reese ... (+4)
  • Alicia Reese
  • Kade Barr
  • Matthew McCartney
  • Michael Pachter
Carole Braudeau
  • Carole Braudeau

Credit Morning 05/15/2025

Maxeda: solid Q4 results and Q1 expected to be strong. Further bond buybacks.|Ubisoft: sharp decline in 2024/25 earnings, no rebound expected in 2025/26|Forvia is considering selling its spare parts division|Techem Q2 25 results: Good earnings print; ownership change and mandatory call remain open|

Carole Braudeau
  • Carole Braudeau

Morning Crédit 15/05/2025

Maxeda : de bons résultats T4 et un T1 qui devrait l’être tout autant. Poursuite des rachats de dettes.|Ubisoft : résultats 2024/25 en forte baisse, pas de rebond attendu en 2025/26|Forvia envisagerait la cession de sa division de pièces détachées|Techem Q2 25 results: Good earnings print; ownership change and mandatory call remain open|

Alicia Reese ... (+4)
  • Alicia Reese
  • Kade Barr
  • Matthew McCartney
  • Michael Pachter
 PRESS RELEASE

Ubisoft Reports Full-Year 2024-25 Earnings Figures

Ubisoft Reports Full-Year 2024-25 Earnings Figures UBISOFT REPORTS FULL-YEAR 2024-25 EARNINGS FIGURES Assassin’s Creed® Shadows release prompted very strong praise from players and delivered a solid performance, clearly ahead of Assassin’s Creed® Odyssey, highlighting the strength of the brand. FY2024-25 performance broadly in line with targets, FCF at €128m: Net bookings: €1.85bn, slightly below objective, mainly reflecting lower than expected partnerships, notably due to a timing impactNon-IFRS operating income in line with guidance Free Cash Flow ahead of target driven by cash flow ...

 PRESS RELEASE

Ubisoft annonce ses résultats pour l’exercice 2024-25

Ubisoft annonce ses résultats pour l’exercice 2024-25 UBISOFT ANNONCE SES RÉSULTATS POUR L’EXERCICE 2024-25 Le lancement d’Assassin’s Creed® Shadows a suscité des retours très positifs de la part des joueurs et a enregistré une performance solide, nettement supérieure à celle d’Assassin’s Creed Odyssey, illustrant la force de la marque. Performance de l’exercice 2024-25 globalement en ligne avec les objectifs Net bookings : 1,85 Mds€, légèrement en dessous de l’objectif, principalement en raison de partenariats inférieurs aux attentes, notamment lié à un impact de timingRésultat opér...

 PRESS RELEASE

Informations sur les droits de vote et les actions au 30 avril 2025

Informations sur les droits de vote et les actions au 30 avril 2025 Le 9 mai 2025 Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social   Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Place de cotation :        Euronext ParisCompartiment :        Compartiment ACode ISIN :                FR0000054470Site web :                 Date Nombre total d’actions composant le capital social Nombre total de droits de vote Total brut (1) Total net (2) 30/04/2025 130 848 866 143 648 674 143 648 674         Le nom...

Alicia Reese ... (+4)
  • Alicia Reese
  • Kade Barr
  • Matthew McCartney
  • Michael Pachter
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch